CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts
暂无分享,去创建一个
A. Tefferi | M. Patnaik | C. Hanson | T. Lasho | C. Finke | A. Belachew
[1] P. Guglielmelli,et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. , 2014, Blood.
[2] F. Passamonti,et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons , 2014, Leukemia.
[3] G. Superti-Furga,et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.
[4] J. D. Fitzpatrick,et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.
[5] A. Tefferi,et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance , 2013, American journal of hematology.
[6] A. Tefferi,et al. SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patients , 2012, Leukemia.
[7] G. Garcia-Manero,et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. , 2012, Blood.
[8] A. Tefferi,et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients , 2011, Leukemia.
[9] A. Tefferi,et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. , 2011, Blood.
[10] A. Schmitt-Graeff,et al. Essential thrombocythemia with ringed sideroblasts: a heterogeneous spectrum of diseases, but not a distinct entity. , 2002, Haematologica.